II2.F INSPIREMD 1/18 DL-0001
- Market cap
- EUR 26.7M
- P/E
- -
- P/B
- 1.05x
- ROE
- -177.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is II2.F undervalued?
Graham numberThe Graham number of INSPIREMD 1/18 DL-0001 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
INSPIREMD 1/18 DL-0001 fundamental analysis
No fundamental analysis for INSPIREMD 1/18 DL-0001 yet.
INSPIREMD 1/18 DL-0001 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About INSPIREMD 1/18 DL-0001
InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally. It offers MicroNet, a biocompatible polymer mesh material for medical implants, as well as for treating plaque prolapse and embolization; CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; C…
Full company profileINSPIREMD 1/18 DL-0001 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
INSPIREMD 1/18 DL-0001 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 4.50M | 5.17M | 6.21M | 7.01M | 8.98M | 10.3M |
| Gross Profit | 754K | 1.12M | 1.81M | 1.51M | 2.65M | -174K |
| Operating Income | -14.7M | -18.7M | -21.1M | -33.5M | -49.6M | -56.8M |
| EBITDA | - | -18.5M | -20.9M | -33.2M | -49.1M | -56.2M |
| Net Income | -14.9M | -18.5M | -19.9M | -32.0M | -48.8M | -56.0M |
| EPS | -1.80 | -2.22 | -0.91 | -1.20 | -1.16 | -1.20 |
| Balance Sheet | ||||||
| Total Assets | 39.7M | 24.7M | 47.6M | 46.8M | 69.4M | 44.6M |
| Total Liabilities | 6.18M | 7.26M | 8.14M | 10.7M | 14.2M | 13.1M |
| Shareholders' Equity | 33.5M | 17.4M | 39.5M | 36.1M | 55.2M | 31.5M |
| Cash & Short-term Investments | 12.0M | 4.63M | 9.64M | 18.9M | 8.94M | 15.1M |
| Cash Flow | ||||||
| Operating Cash Flow | -13.2M | -15.5M | -16.4M | -21.9M | -35.1M | -46.5M |
| Capital Expenditure | 344K | 473K | 381K | 1.40M | 1.66M | 1.05M |
| Free Cash Flow | -13.6M | -16.0M | -16.8M | -23.3M | -36.8M | -47.5M |
| Ratios | ||||||
| ROE | -44.5% | -106.3% | -50.4% | -88.7% | -88.4% | -177.8% |
| ROA | -37.6% | -75.0% | -41.8% | -68.4% | -70.3% | -125.5% |
| Net Profit Margin | -331.9% | -357.6% | -321.0% | -456.6% | -543.3% | -541.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
INSPIREMD 1/18 DL-0001 dividends
INSPIREMD 1/18 DL-0001 has not paid dividends in the last 5 fiscal years.
Last stock split: 1:15 on Apr 27, 2021.
Who owns INSPIREMD 1/18 DL-0001
- Insiders 19.98%
- Institutions 46.58%
- Public & others 33.44%
- Shares outstanding 46.5M
- Free float 28.7M
INSPIREMD 1/18 DL-0001 company profile
- Company name
- INSPIREMD 1/18 DL-0001
- Ticker
- II2.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 127
- Fiscal year end
- December
- Address
- 6303 Waterford District Drive, Miami, FL, United States, 33126
- Phone
- 888 776 6804
- Website
- inspiremd.com
About INSPIREMD 1/18 DL-0001
InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally. It offers MicroNet, a biocompatible polymer mesh material for medical implants, as well as for treating plaque prolapse and embolization; CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Carotid Stent System; and SwitchGuard neuroprotection system to provide flow reversal of cerebral protection in carotid interventions, as well as treating acute stroke with tandem lesions. The company was founded in 2005 and is headquartered in Miami, Florida.
INSPIREMD 1/18 DL-0001 management
9- Mr. Marvin L. SlosmanPresident, CEO & Director · born 1964
- Mr. Michael A. LawlessCFO, Secretary & Treasurer · born 1969
- Mr. Vince TurturroSenior Vice President of Global Operations & Engineering
- Ms. Kathleen KennedySenior Vice President of Global Sales & Marketing
- Ms. Donna DeChantVice President of Human Resources & Organizational Development
- Mr. Amir KohenExecutive VP of Finance & Regional Manager
- Dr. Peter A. Soukas M.D.Chief Medical Officer
- Ms. Sonali DewanSenior Vice President of Regulatory & Medical Affairs and Quality Assurance
- Dr. Sol J. Barer Ph.D.Special Advisor to the Board · born 1947